MINI REVIEW Oncolytic virotherapy as a personalized cancer vaccine

Cancer is a leading cause of death with increasing incidence and mortality due to growth of the aging population. Although conventional treatments (e.g., surgery, radiation and chemotherapies) have made significant impact in overall patient survival and quality of life in the past decades, the majority of malignancies remain incurable and unmanageable. Therapeutic cancer vaccines recently emerge as a promising new cancer treatment. Passive immunization using therapeutic antibodies against tumor-associated antigens (TAAs) has been shown to prolong survival of patients with certain solid tumors and leukemias, particularly when combined with conventional treatments. Active immunization with

[1]  A. Aruga.  [Dendritic cell-based cancer immunotherapy]. , 2010, Nihon rinsho. Japanese journal of clinical medicine.

[2]  R. Weissleder,et al.  Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. , 2007, Journal of the National Cancer Institute.

[3]  O. Wildner,et al.  Therapeutic immune response induced by intratumoral expression of the fusogenic membrane protein of vesicular stomatitis virus and cytokines encoded by adenoviral vectors. , 2007, International journal of molecular medicine.

[4]  A. Arnold,et al.  Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy , 2007, Gene Therapy.

[5]  S. Steinberg,et al.  Clinical safety of a viral vector based prostate cancer vaccine strategy. , 2007, The Journal of urology.

[6]  Erwin G. Van Meir,et al.  Erratum: Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4 (Cancer Research (2007) 67, (6872-6881)) , 2007 .

[7]  Zihua Zeng,et al.  Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. , 2007, Cancer research.

[8]  Tae Woo Kim,et al.  Chemotherapy Enhances CD8+ T Cell-mediated Antitumor Immunity Induced by Vaccination With Vaccinia Virus. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  Erwin G. Van Meir,et al.  Targeted cancer gene therapy using a hypoxia inducible factor dependent oncolytic adenovirus armed with interleukin-4. , 2007, Cancer research.

[10]  O. Wildner,et al.  Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer , 2007, Molecular Cancer Therapeutics.

[11]  O. Wildner,et al.  In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines. , 2007, World journal of gastroenterology.

[12]  M. Aprahamian,et al.  Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. , 2007, Oncology reports.

[13]  S. Xue,et al.  Enhancing immune responses for cancer therapy. , 2007, Cellular & molecular immunology.

[14]  O. Wildner,et al.  Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis. , 2007, Human gene therapy.

[15]  E. Gilboa.  DC-based cancer vaccines. , 2007, The Journal of clinical investigation.

[16]  C. Contag,et al.  Combining immune cell and viral therapy for the treatment of cancer , 2007, Cellular and Molecular Life Sciences.

[17]  Xiaoliu Zhang,et al.  Induction of strong antitumor immunity by an HSV‐2‐based oncolytic virus in a murine mammary tumor model , 2007, The journal of gene medicine.

[18]  L. Bracci,et al.  Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration , 2007, Clinical Cancer Research.

[19]  W. Gillanders,et al.  Defining the Ability of Cyclophosphamide Preconditioning to Enhance the Antigen-specific CD8+ T-cell Response to Peptide Vaccination: Creation of a Beneficial Host Microenvironment Involving Type I IFNs and Myeloid Cells , 2007, Journal of immunotherapy.

[20]  Xiaoliu Zhang,et al.  Virotherapy with a Type 2 Herpes Simplex Virus–Derived Oncolytic Virus Induces Potent Antitumor Immunity against Neuroblastoma , 2007, Clinical Cancer Research.

[21]  Ralph Weissleder,et al.  Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  R. Coombes,et al.  A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor , 2006, Clinical Cancer Research.

[23]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[24]  Hoguen Kim,et al.  Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model , 2006, Clinical Cancer Research.

[25]  Jiwon Kim,et al.  Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[26]  M. Caligiuri,et al.  Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses , 2006, Proceedings of the National Academy of Sciences.

[27]  O. Wildner,et al.  Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy , 2006, Molecular Cancer Therapeutics.

[28]  Yu Seong Lee,et al.  Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect , 2006, Gene Therapy.

[29]  R. Martuza,et al.  Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers , 2006, Cancer Gene Therapy.

[30]  F. Errington,et al.  Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  N. D. Di Paolo,et al.  Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses. , 2006, Cancer research.

[32]  H. Fukuhara,et al.  Triple Combination of Oncolytic Herpes Simplex Virus-1 Vectors Armed with Interleukin-12, Interleukin-18, or Soluble B7-1 Results in Enhanced Antitumor Efficacy , 2006, Clinical Cancer Research.

[33]  E. Chiocca,et al.  Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus. , 2005, Cancer research.

[34]  E. Jaffee,et al.  Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. , 2005, Cancer research.

[35]  R. Rosenthal,et al.  Clinical applications of recombinant virus-based cancer immunotherapy , 2005, Expert opinion on biological therapy.

[36]  V. Schirrmacher.  Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory , 2005, Cancer Immunology, Immunotherapy.

[37]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Nemunaitis,et al.  Fighting cancer with vaccinia virus: teaching new tricks to an old dog. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  C. Rooney,et al.  Targeted delivery of adenoviral vectors by cytotoxic T cells. , 2004, Blood.

[40]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Xiaoliu Zhang,et al.  Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[42]  B. Chauffert,et al.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative , 2004, European journal of immunology.

[43]  A. Harris,et al.  Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. , 2003, Cancer research.

[44]  L. Trentin,et al.  Ifosfamide and Cyclophosphamide: Effects on Immunosurveillance , 2003, Oncology.

[45]  Wenhong Ren,et al.  A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. , 2003, Cancer research.

[46]  R. Vile,et al.  Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  R. Coffin,et al.  ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties , 2003, Gene Therapy.

[48]  Atique U. Ahmed,et al.  Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. , 2002, Cancer research.

[49]  P. Fournier,et al.  Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. , 2002, International journal of oncology.

[50]  Stephen C. Jameson,et al.  Maintaining the norm: T-cell homeostasis , 2002, Nature Reviews Immunology.

[51]  J. Blattman,et al.  CD8+ T cell responses: it's all downhill after their prime ... , 2002, Nature Immunology.

[52]  H. Wakimoto,et al.  The complement response against an oncolytic virus is species-specific in its activation pathways. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  R. Crystal,et al.  Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. , 2001, Cancer research.

[54]  E. Jaffee,et al.  Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. , 2001, Cancer research.

[55]  A. Adachi,et al.  Physiological significance of apoptosis in animal virus infection. , 2000, Microbes and infection.

[56]  Stuart K. Calderwood,et al.  HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine , 2000, Nature Medicine.

[57]  H. Kampinga,et al.  Heat shock protein 70 (Hsp70) stimulates proliferation and cytolytic activity of natural killer cells. , 1999, Experimental hematology.

[58]  D. Louis,et al.  Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses , 1999, Nature Medicine.

[59]  H. Ploegh,et al.  Inhibition of Major Histocompatibility Complex Class I Antigen Presentation in Pig and Primate Cells by Herpes Simplex Virus Type 1 and 2 ICP47 , 1998, Journal of Virology.

[60]  H. Maguire,et al.  Active specific immunization in the treatment of patients with melanoma. , 1996, Seminars in oncology.

[61]  R. Kempf,et al.  Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. , 1988, Cancer research.

[62]  H. Maguire,et al.  Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. , 1984, Cancer research.

[63]  P. Askenase,et al.  Augmentation of delayed-type hypersensitivity by doses of cyclophosphamide which do not affect antibody responses , 1975, The Journal of experimental medicine.

[64]  A. Melcher,et al.  Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy , 2008, Nature Medicine.

[65]  M. Carroll,et al.  Viral vectors for cancer immunotherapy. , 2006, Frontiers in bioscience : a journal and virtual library.

[66]  F. Errington,et al.  Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming , 2006, Gene Therapy.

[67]  H. Wakimoto,et al.  Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis , 2004, Gene Therapy.

[68]  R. Martuza,et al.  In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent antitumor immunity. , 2001, Cancer research.

[69]  V. Rozados,et al.  Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model , 2001, Cancer Immunology, Immunotherapy.

[70]  V. Schirrmacher,et al.  Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus , 1999, Gene Therapy.